Trials / Completed
CompletedNCT03747224
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- Arrowhead Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and pharmacodynamics of single- and multiple doses of ARO-ANG3 in healthy adult volunteers and in dyslipidemic patients including familial hypercholesterolemia and severe hypertriglyceridemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARO-ANG3 | single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections |
| DRUG | sterile normal saline (0.9% NaCl) | calculated volume to match active treatment |
Timeline
- Start date
- 2019-01-07
- Primary completion
- 2021-05-17
- Completion
- 2021-05-17
- First posted
- 2018-11-20
- Last updated
- 2025-12-24
Locations
6 sites across 2 countries: Australia, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03747224. Inclusion in this directory is not an endorsement.